414 related articles for article (PubMed ID: 32265933)
1. Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors.
Gibellini L; De Biasi S; Porta C; Lo Tartaro D; Depenni R; Pellacani G; Sabbatini R; Cossarizza A
Front Immunol; 2020; 11():490. PubMed ID: 32265933
[TBL] [Abstract][Full Text] [Related]
2. How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
Denis M; Duruisseaux M; Brevet M; Dumontet C
Front Immunol; 2020; 11():492. PubMed ID: 32265935
[TBL] [Abstract][Full Text] [Related]
3. Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review.
Rochigneux P; Garcia AJ; Chanez B; Madroszyk A; Olive D; Garon EB
Front Immunol; 2020; 11():1036. PubMed ID: 32670271
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors.
Perrier A; Didelot A; Laurent-Puig P; Blons H; Garinet S
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708698
[TBL] [Abstract][Full Text] [Related]
5. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.
Zhang Y; Zhang Z
Cell Mol Immunol; 2020 Aug; 17(8):807-821. PubMed ID: 32612154
[TBL] [Abstract][Full Text] [Related]
6. Monitoring the immune competence of cancer patients to predict outcome.
Chang S; Kohrt H; Maecker HT
Cancer Immunol Immunother; 2014 Jul; 63(7):713-9. PubMed ID: 24487923
[TBL] [Abstract][Full Text] [Related]
7. Systems immune monitoring in cancer therapy.
Greenplate AR; Johnson DB; Ferrell PB; Irish JM
Eur J Cancer; 2016 Jul; 61():77-84. PubMed ID: 27155446
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiome and cancer immunotherapy.
Sun JY; Yin TL; Zhou J; Xu J; Lu XJ
J Cell Physiol; 2020 May; 235(5):4082-4088. PubMed ID: 31663125
[TBL] [Abstract][Full Text] [Related]
9. Tissue biomarkers of immune checkpoint inhibitor therapy.
Davoudi F; Moradi A; Sadeghirad H; Kulasinghe A
Immunol Cell Biol; 2024 Mar; 102(3):179-193. PubMed ID: 38228572
[TBL] [Abstract][Full Text] [Related]
10. Are there, or shall we discover, biomarkers to guide PD-1 inhibition?
Ascierto PA; de Mello RA
Immunotherapy; 2016 Jun; 8(6):681-6. PubMed ID: 27197537
[TBL] [Abstract][Full Text] [Related]
11. Immune and metabolic checkpoints blockade: Dual wielding against tumors.
Kazemi MH; Najafi A; Karami J; Ghazizadeh F; Yousefi H; Falak R; Safari E
Int Immunopharmacol; 2021 May; 94():107461. PubMed ID: 33592403
[TBL] [Abstract][Full Text] [Related]
12. Single-Cell Proteomics for Cancer Immunotherapy.
Li L; Yan S; Lin B; Shi Q; Lu Y
Adv Cancer Res; 2018; 139():185-207. PubMed ID: 29941105
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action.
Take Y; Koizumi S; Nagahisa A
Front Immunol; 2020; 11():324. PubMed ID: 32210957
[TBL] [Abstract][Full Text] [Related]
14. From Oncogenic Signaling Pathways to Single-Cell Sequencing of Immune Cells: Changing the Landscape of Cancer Immunotherapy.
Derakhshani A; Rostami Z; Safarpour H; Shadbad MA; Nourbakhsh NS; Argentiero A; Taefehshokr S; Tabrizi NJ; Kooshkaki O; Astamal RV; Singh PK; Taefehshokr N; Alizadeh N; Silvestris N; Baradaran B
Molecules; 2021 Apr; 26(8):. PubMed ID: 33920054
[TBL] [Abstract][Full Text] [Related]
15. Single-cell Analysis Technologies for Immuno-oncology Research: from Mechanistic Delineation to Biomarker Discovery.
Bai Z; Su G; Fan R
Genomics Proteomics Bioinformatics; 2021 Apr; 19(2):191-207. PubMed ID: 34000441
[TBL] [Abstract][Full Text] [Related]
16. Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer.
Noguchi E; Shien T; Iwata H
Jpn J Clin Oncol; 2021 Mar; 51(3):321-332. PubMed ID: 33324990
[TBL] [Abstract][Full Text] [Related]
17. Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.
Law AMK; Valdes-Mora F; Gallego-Ortega D
Cells; 2020 Feb; 9(3):. PubMed ID: 32121014
[TBL] [Abstract][Full Text] [Related]
18. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
Hou A; Hou K; Huang Q; Lei Y; Chen W
Front Immunol; 2020; 11():783. PubMed ID: 32508809
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Immune checkpoint inhibitors benefit from routinely measurable peripheral blood parameters.
Voutsadakis IA
Chin Clin Oncol; 2020 Apr; 9(2):19. PubMed ID: 32279524
[TBL] [Abstract][Full Text] [Related]
20. Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy.
Zemek RM; Chin WL; Nowak AK; Millward MJ; Lake RA; Lesterhuis WJ
Front Immunol; 2020; 11():223. PubMed ID: 32133005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
